ONCOMINE analysis showed that STMN2 transcripts were 1.116-fold higher in cancer compared with normal samples from Bonome Ovarian Statistics (P = 6.37E−5), indicating that the expression of STMN2 was up-regulated in ovarian cancer (Figure 4C). This evidence concerns the gene STMN2 and ovarian carcinoma.